NASDAQ:ALVR AlloVir (ALVR) Stock Price, News & Analysis $4.83 +0.13 (+2.77%) As of 05/20/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsInsider TradesSEC FilingsTrendsBuy This Stock About AlloVir Stock (NASDAQ:ALVR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get AlloVir alerts:Sign Up Key Stats Today's Range$4.56▼$4.9150-Day Range$4.70▼$10.0052-Week Range$7.96▼$24.15Volume53,234 shsAverage Volume15,685 shsMarket Capitalization$24.36 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview AlloVir, Inc. is a clinical-stage biopharmaceutical company specializing in the development of off-the-shelf, allogeneic virus-specific T-cell immunotherapies for the prevention and treatment of life-threatening viral infections in immunocompromised patients. The company’s proprietary Multi-Virus-Targeting Cell (MTC) platform enables the rapid identification, isolation and expansion of virus-specific T cells from healthy donors, with the aim of offering broad coverage against multiple clinically significant viruses. AlloVir’s pipeline includes several product candidates designed to address unmet needs in transplant medicine and other immunosuppressed settings. ALVR105 is being evaluated for the treatment of Epstein-Barr virus (EBV)-positive post-transplant lymphoproliferative disease, while ALVR106 and ALVR107 are targeted against BK virus and cytomegalovirus (CMV), respectively. A fourth candidate, ALVR108, is being developed as a multivirus therapy to target a combination of common viral pathogens. All programs are in various stages of clinical or preclinical development, reflecting the company’s commitment to advancing novel immunotherapies through regulatory milestones. Headquartered in Boston, Massachusetts, AlloVir serves a global market of transplant centers and healthcare institutions. The company’s leadership team brings together expertise in cell therapy, immunology and clinical development, supporting collaborations with academic centers and strategic partners to accelerate product development. AlloVir is publicly traded on the NASDAQ under the ticker symbol ALVR.AI Generated. May Contain Errors. Read More Receive ALVR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AlloVir and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ALVR Stock News HeadlinesALLOVIR INVESTIGATION: Bragar Eagel & Squire, P.C. Continues Investigation into AlloVir, Inc. on Behalf of Long-Term StockholdersOctober 16, 2025 | globenewswire.comALLOVIR ALERT: Bragar Eagel & Squire, P.C. is Investigating AlloVir, Inc. ...August 6, 2025 | gurufocus.comTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.May 21 at 1:00 AM | Banyan Hill Publishing (Ad)ALLOVIR ALERT: Bragar Eagel & Squire, P.C. is Investigating AlloVir, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmAugust 6, 2025 | globenewswire.comKalaris Announces Closing of Merger with AlloVirMarch 18, 2025 | globenewswire.comAlloVir shareholders approve merger with Kalaris TherapeuticsMarch 14, 2025 | investing.comAlloVir, Inc.: Kalaris and AlloVir Announce Stockholder Approval of MergerMarch 13, 2025 | finanznachrichten.deKalaris, AlloVir announce stockholder approval of mergerMarch 13, 2025 | markets.businessinsider.comSee More Headlines ALVR Stock Analysis - Frequently Asked Questions How have ALVR shares performed this year? AlloVir's stock was trading at $8.44 at the beginning of the year. Since then, ALVR shares have decreased by 42.8% and is now trading at $4.83. How were AlloVir's earnings last quarter? AlloVir, Inc. (NASDAQ:ALVR) announced its earnings results on Wednesday, August, 14th. The company reported ($1.15) EPS for the quarter, topping the consensus estimate of ($2.30) by $1.15. When did AlloVir's stock split? Shares of AlloVir reverse split on Thursday, January 16th 2025.The 1-23 reverse split was announced on Wednesday, January 15th 2025. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, January 15th 2025. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. When did AlloVir IPO? AlloVir (ALVR) raised $276 million in an initial public offering (IPO) on Thursday, July 30th 2020. The company issued 16,250,000 shares at $16.00-$18.00 per share. Morgan Stanley, J.P. Morgan, SVB Leerink and Piper Sandler served as the underwriters for the IPO. How do I buy shares of AlloVir? Shares of ALVR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of AlloVir own? Based on aggregate information from My MarketBeat watchlists, some other companies that AlloVir investors own include Waste Connections (WCN), American Water Works (AWK), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), AUO (AUOTY), DiamondRock Hospitality (DRH) and Triple Flag Precious Metals (TFPM). Company Calendar Last Earnings8/14/2024Today5/21/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ALVR CIK1754068 Webwww.allovir.com Phone617-433-2605FaxN/AEmployees110Year Founded2013Profitability EPS (Trailing Twelve Months)($20.23) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$190.42 million Net MarginsN/A Pretax MarginN/A Return on Equity-71.03% Return on Assets-61.27% Debt Debt-to-Equity RatioN/A Current Ratio86.78 Quick Ratio86.78 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$29.35 per share Price / Book0.16Miscellaneous Outstanding Shares5,043,000Free Float3,425,000Market Cap$24.36 million OptionableNo Data Beta0.63 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free Report This page (NASDAQ:ALVR) was last updated on 5/21/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AlloVir, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AlloVir With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
